Galmed Pharmaceuticals
GLMD
11 hedge funds and large institutions have $140K invested in Galmed Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
74% more capital invested
Capital invested by funds: $80.4K → $140K (+$59.7K)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
10% more funds holding
Funds holding: 10 → 11 (+1)
0.04% less ownership
Funds ownership: 0.46% → 0.42% (-0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$38.5K |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$14.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$8.53K |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
+$3.09K |
| 5 |
PWA
Physician Wealth Advisors
Midvale,
Utah
|
+$35 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$16K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$15.9K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.94K |
GLMD Hedge Fund Activity: Q2 2025 in Review
11 of the 7,610 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2025, worth a combined $140K — up 74% from $80.4K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new GLMD positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $38.5K. The largest seller was Virtu Financial, exiting entirely with an estimated $16K sold.
- 11 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2025, up from 10 in Q1 2025.
- Funds reported $140K of Galmed Pharmaceuticals stock for Q2 2025, up 74% quarter-over-quarter.
- 3 funds opened new Galmed Pharmaceuticals positions in Q2 2025 and 2 closed out, a net change of +1 holder.
- The largest Galmed Pharmaceuticals buyer in Q2 2025 was Morgan Stanley, an estimated $38.5K added.
- The largest Galmed Pharmaceuticals seller in Q2 2025 was Virtu Financial, an estimated $16K sold.
Based on aggregated 13F filings for Q2 2025.